Home/Filings/4/0001209191-21-025846
4//SEC Filing

Thornton Michael Milos 4

Accession 0001209191-21-025846

CIK 0001681682other

Filed

Apr 6, 8:00 PM ET

Accepted

Apr 7, 4:08 PM ET

Size

9.8 KB

Accession

0001209191-21-025846

Insider Transaction Report

Form 4
Period: 2021-03-29
Thornton Michael Milos
Chief Technology Officer
Transactions
  • Award

    Stock Options

    2021-04-05+50,00050,000 total
    Exercise: $2.64Exp: 2031-04-05Common Stock (50,000 underlying)
  • Sale

    Common Stock

    2021-03-29$2.37/sh18,750$44,438274,960 total
  • Sale

    Common Stock

    2021-04-07$2.53/sh15,000$37,950259,960 total
Footnotes (4)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F4]This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022.

Issuer

ENDRA Life Sciences Inc.

CIK 0001681682

Entity typeother

Related Parties

1
  • filerCIK 0001706297

Filing Metadata

Form type
4
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 4:08 PM ET
Size
9.8 KB